Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 3/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
| ▸ | MLYCD | O95822 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TERT | O14746 | 2/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | PTPRC | P08575 | 1/20 | 0.57 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | PTAFR | P25105 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6841880 | 0.82 | ALDH1A1 (0.68) | RAB9APOLBCTSLPTPRCPTPN13 | |
| SCHEMBL3225126 | 0.80 | NPC1 (1.00) | NPC1RAB9APOLBKDM4EMLYCD | |
| SCHEMBL2247862 | 0.80 | CCKBR (0.51) | CTSLPTPRCPTPN13 | |
| SCHEMBL6843653 | 0.80 | NPC1 (0.61) | NPC1RAB9APOLBKDM4EMLYCD | |
| SCHEMBL10674580 | 0.80 | NPC1 (0.69) | NPC1RAB9APOLBKDM4EMLYCD | |
| SCHEMBL7160424 | 0.80 | GRIN1 (0.68) | NPC1RAB9APOLBKDM4EGRIN1 | |
| SCHEMBL14527855 | 0.80 | GRIN1 (0.67) | POLBGRIN1GRIN2AGRIN2BTERT | |
| SCHEMBL2956025 | 0.79 | NPC1 (0.68) | NPC1RAB9APOLBKDM4EMLYCD | |
| SCHEMBL13875721 | 0.79 | GRIN1 (0.67) | NPC1RAB9APOLBGRIN1GRIN2A | |
| SCHEMBL5175136 | 0.78 | GRIN1 (0.66) | POLBGRIN1GRIN2AGRIN2BTERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240096495-A1 | METHOD FOR IDENTIFYING PERSONALIZED THERAPEUTIC STRATEGIES FOR PATIENTS AFFECTED WITH A CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-03-21 | — | — | US | claimed |
| US-11823799-B2 | Method for identifying personalized therapeutic strategies for patients affected with a cancer | UNIVERSITE DE STRASBOURG (FR) | 2023-11-21 | — | — | US | claimed |
| EP-4715067-A2 | METHOD FOR IDENTIFYING PERSONALIZED THERAPEUTIC STRATEGIES FOR PATIENTS AFFECTED WITH A CANCER | Université de Strasbourg (FR) | 2026-03-25 | — | — | EP | disclosed |
| US-20240096495-A1 | METHOD FOR IDENTIFYING PERSONALIZED THERAPEUTIC STRATEGIES FOR PATIENTS AFFECTED WITH A CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-03-21 | — | — | US | disclosed |
| US-11823799-B2 | Method for identifying personalized therapeutic strategies for patients affected with a cancer | UNIVERSITE DE STRASBOURG (FR) | 2023-11-21 | — | — | US | disclosed |
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-01-08 | — | — | US | disclosed |
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2007-02-08 | — | — | US | disclosed |
| WO-2007014226-A2 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATION AND STROKE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032496-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | PARP1, PARP12, PARP11 | NPC1 996/4885RAB9A 2534/4885POLB 539/4885 |
| US-20090012088-A1 | Compounds for the Treatment of Neurodegeneration and Stroke | PARP1, PARP12, PARP11 | NPC1 996/4885RAB9A 2534/4885POLB 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.